✨ Free AI Report
Gland Pharma Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Gland Pharma Limited
Company Research

Gland Pharma Limited: Business Overview, Financials & Competitive Analysis

Gland Pharma Limited scores 6/10 on the AskCyborg Cyborg Score (Solid). Defensive injectable pharma play with global scale but facing near-term growth headwinds; positioning for long-term expansion in complex generics. The company faced revenue decline of 0.85% in 2024 and earnings decreased 9.57%, though recent quarters show margin stability. GLAND underperformed both the Indian pharmaceuticals industry and broader market over.

What is Gland Pharma Limited's industry? Gland Pharma Limited (glandpharma.com) operates in Pharmaceutical Manufacturing - Injectable Formulations & APIs. AskCyborg classifies Gland Pharma Limited under Pharmaceutical Manufacturing - Injectable Formulations & APIs in its company registry.

Gland Pharma manufactures and sells injectable formulations globally while developing pharmaceutical active pharmaceutical ingredients including complex molecules like low molecular weight heparins, corticosteroids, p...

6/ 10Solid

Cyborg Score thesis

Defensive injectable pharma play with global scale but facing near-term growth headwinds; positioning for long-term expansion in...

Read the full analyst-debate transcript →
Industry Pharmaceutical Manufacturing - Injectable Formulations & APIs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Gland Pharma Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Gland Pharma Limited

AskCyborg analysts argue the bull and bear cases for Gland Pharma Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Gland Pharma Limited OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Gland Pharma Limited Overview

Pro stress-test →

Gland Pharma manufactures and sells injectable formulations globally while developing pharmaceutical active pharmaceutical ingredients including complex molecules like low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. Established in Hyderabad in 1978, the company has grown from a contract manufacturer to become one of the largest and fastest-growing injectable-focused companies with global presence across 60 countries.

Strategic Profile

Pro stress-test →

Operating under a business-to-business model, the company has demonstrated excellence in developing, manufacturing and marketing complex injectables with presence across the value chain enabling exponential growth. Gland Pharma is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Competitive Landscape

Pro stress-test →

Gland Pharma is covered by 26 analysts with 12 providing revenue/earnings estimates. The company operates in India's injectable pharmaceuticals space competing against diversified pharma majors. The company maintains global presence in 60 countries operating on a B2B model in India, USA, Canada, Australia, and European countries.

Industry Context

Gland Pharma Limited operates in Pharmaceutical Manufacturing - Injectable Formulations & APIs.

Key facts

Founded: 1978 · Headquarters: Hyderabad, India · Revenue: ₹5,830.11 Cr (FY2025-26) · Market cap: ₹31,065 Cr

What the analysts stress-tested

The top findings that survived the multi-agent debate for Gland Pharma Limited.

  • Q2 FY2025-26 revenue declined 0.1% YoY to ₹1486.88 crore with net profit down 9.6% to ₹183.68 crore, though full-year FY2025-26 revenue reached ₹5830.11 crore with profit of ₹698.53 crore.
  • Company pursuing aggressive capacity expansion, complex product launches with diversification into emerging markets and advanced manufacturing formats to enhance earnings stability.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Analyst/investor meeting with Investec scheduled for February 12, 2026
  • Sept 2025Q2 FY2025-26 results released showing YoY revenue decline with margin pressures
  • +1 moreTrack every material event for Gland Pharma Limited as it happens. Explore monitoring →
Get alerted when Gland Pharma Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Injectable FormulationsGlobal injectable and pharmaceutical major→Injectable FormulationsIndian pharmaceutical manufacturer→Injectable FormulationsAPI and formulation manufacturer→

Compare Gland Pharma Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Gland Pharma Limited operates in Pharmaceutical Manufacturing - Injectable Formulations & APIs. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Manufacturing - Injectable Formulations & APIs research →
NEW · MCP server

Ask your AI assistant about Gland Pharma Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Gland Pharma Limited and its top competitor on Cyborg Score”
“What did Gland Pharma Limited do this quarter?”
“Is Gland Pharma Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Gland Pharma Limited do?+
Gland Pharma manufactures and sells injectable formulations globally while developing pharmaceutical active pharmaceutical ingredients including complex molecules like low molecular weight heparins, corticosteroids, p...
What is Gland Pharma Limited's Cyborg Score?+
Gland Pharma Limited has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Gland Pharma Limited's main competitors?+
Named competitors include Injectable Formulations, Injectable Formulations, Injectable Formulations. The full competitive landscape is in the AskCyborg report.
How can I get the full Gland Pharma Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Gland Pharma Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Gland Pharma Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.